HK1060152A1 - Conditionally replicating viral vectors and their use - Google Patents

Conditionally replicating viral vectors and their use

Info

Publication number
HK1060152A1
HK1060152A1 HK04103067.8A HK04103067A HK1060152A1 HK 1060152 A1 HK1060152 A1 HK 1060152A1 HK 04103067 A HK04103067 A HK 04103067A HK 1060152 A1 HK1060152 A1 HK 1060152A1
Authority
HK
Hong Kong
Prior art keywords
image
viral
conditionally replicating
vector
replicating viral
Prior art date
Application number
HK04103067.8A
Other languages
English (en)
Inventor
Boro Dropulic
Paula M Pitha-Rowe
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of HK1060152A1 publication Critical patent/HK1060152A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK04103067.8A 1995-11-28 2004-04-30 Conditionally replicating viral vectors and their use HK1060152A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56345995A 1995-11-28 1995-11-28

Publications (1)

Publication Number Publication Date
HK1060152A1 true HK1060152A1 (en) 2004-07-30

Family

ID=24250568

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103067.8A HK1060152A1 (en) 1995-11-28 2004-04-30 Conditionally replicating viral vectors and their use

Country Status (19)

Country Link
EP (2) EP0871757B1 (fr)
JP (2) JP2000503527A (fr)
KR (1) KR100537458B1 (fr)
CN (3) CN100390291C (fr)
AT (2) ATE455858T1 (fr)
AU (3) AU1124997A (fr)
BR (1) BR9612574A (fr)
CA (1) CA2236868C (fr)
CZ (1) CZ294170B6 (fr)
DE (2) DE69638120D1 (fr)
DK (1) DK0871757T3 (fr)
ES (1) ES2188802T3 (fr)
HK (1) HK1060152A1 (fr)
IL (2) IL124636A0 (fr)
NO (1) NO329619B1 (fr)
NZ (1) NZ324157A (fr)
PT (1) PT871757E (fr)
RU (1) RU2270250C2 (fr)
WO (1) WO1997020060A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037669A4 (fr) * 1997-12-12 2003-04-02 Cell Genesys Inc Emploi therapeutique de vecteurs lentiviraux
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
AU9307501A (en) * 2000-09-22 2002-04-02 Virxsys Improved conditionally replicating vectors, methods for their production and use
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
HUE036103T2 (hu) 2007-12-11 2018-06-28 Univ North Carolina Chapel Hill Polipurin szakaszon módosított retrovirális vektorok
KR102162111B1 (ko) * 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
CA3225013A1 (fr) * 2015-02-24 2016-09-01 Bioatla, Llc Proteines conditionnellement actives
CN104711294A (zh) * 2015-04-02 2015-06-17 扬州大学 一种基于禽网状内皮组织增生症病毒ltr的真核表达线性化载体的构建方法及应用
GB2543730A (en) * 2015-05-26 2017-05-03 Andrzejewski Slawomir Use of replication competent vector to eradicate viral latency presented on human immunodeficiency virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1994026877A1 (fr) * 1993-05-17 1994-11-24 The Regents Of The University Of California Therapie genique ribozymique contre l'infection par le vih et contre le sida
ES2260376T3 (es) * 1994-01-05 2006-11-01 Gene Shears Pty Limited Ribozimas dirigidas contra una secuencia tat del vih.
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof

Also Published As

Publication number Publication date
JP2000503527A (ja) 2000-03-28
CN1940076A (zh) 2007-04-04
IL124636A (en) 2009-12-24
ATE234362T1 (de) 2003-03-15
EP0871757B1 (fr) 2003-03-12
JP4384146B2 (ja) 2009-12-16
DE69626681T2 (de) 2004-02-12
NO329619B1 (no) 2010-11-22
EP1380650A1 (fr) 2004-01-14
AU1124997A (en) 1998-06-19
AU767620B2 (en) 2003-11-20
EP0871757A1 (fr) 1998-10-21
CN100390291C (zh) 2008-05-28
ES2188802T3 (es) 2003-07-01
CN1207775A (zh) 1999-02-10
AU2004200663B2 (en) 2007-07-05
CA2236868A1 (fr) 1997-06-05
CA2236868C (fr) 2014-01-21
AU1000001A (en) 2001-05-17
BR9612574A (pt) 2000-04-25
KR100537458B1 (ko) 2008-09-08
KR19990071728A (ko) 1999-09-27
RU2270250C2 (ru) 2006-02-20
DK0871757T3 (da) 2003-07-14
CZ162498A3 (cs) 1998-12-16
IL124636A0 (en) 1998-12-06
CZ294170B6 (cs) 2004-10-13
NO982418L (no) 1998-07-27
PT871757E (pt) 2003-08-29
NO982418D0 (no) 1998-05-27
ATE455858T1 (de) 2010-02-15
DE69638120D1 (de) 2010-03-11
EP1380650B1 (fr) 2010-01-20
JP2007014341A (ja) 2007-01-25
DE69626681D1 (de) 2003-04-17
NZ324157A (en) 2000-10-27
CN1651577A (zh) 2005-08-10
AU2004200663A1 (en) 2004-04-08
WO1997020060A1 (fr) 1997-06-05

Similar Documents

Publication Publication Date Title
CY1120209T1 (el) Αλληλουχιες αδενο-εξαρτωμενου ιου (aav) οροτυπου 9, φορεις που τον περιεχουν και χρησεις αυτων
IL207348A0 (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them, and use thereof in the manufacture of medicinal products for producing recombinant proteins in vivo
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
EP1312679B8 (fr) Virus MVA recombinants et leur utilisation
CA2283464A1 (fr) Clone d'adn fonctionnel du virus de l'hepatite c (hcv) et ses utilisations
WO1996011279A3 (fr) Reponse immunitaire amelioree par l'introduction par recombinaison du gene de la cytokine et/ou du gene de la proteine co-stimulatrice b7 dans un systeme d'expression virale
HUP0101432A2 (hu) Rák kezelésére és megelőzésére alkalmas peptidek
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
FR2705361B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
IL124636A0 (en) Conditionally replicating viral vectors and their use
AUPN477695A0 (en) Gene therapy
DK0839194T3 (da) Varianter af P53-proteinet og terapeutiske anvendelser
ZA941426B (en) Recombinant viruses and their use in gene therapy
DK0843731T3 (da) Adenovirusvektorer til genterapi
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
WO1996040764A3 (fr) Nucleotide et sequences d'acides amines de la region 1 hypervariable du gene e2 du virus de l'hepatite c
EP0789563A4 (fr) Vaccins contre le virus de l'hepatite
AU5104096A (en) Novel recombinant dna vectors for gene therapy
WO2001011063A3 (fr) Vecteurs de recombinaison pour le transfert de genes, leurs procedes de production et leur utilisation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131127